HEIDELTEC-team: Double success
Posted June 15 2018
Great success for the HEIDELTEC-team in the “Gründerpreis Baden-Württemberg 2018” and the "ACHEMA-Gründerpreis" competition.

The Team of HEIDELTEC, being located within the Institute of Pharmacy and Molecular Biotechnology (IPMB) was ranked 3rd in the “Gründerpreis Baden-Württemberg 2018”, which was endowed with 5000,- Euro. In addition, the team won the ACHEMA-Gründerpreis 2018 (10.000 Euros). Subject of research and development of HEIDELTEC (Dr. Silvia Pantze, Dr. Robin Tremmel, Dr. Frieder Helm und Moritz Stadler) is the creation of a solid oral dosage form for peptides and proteins, drugs which otherwise can only be applied by intravenous injections. A short summary can be found on Youtube.



Founded in 2017, Heidelberg Delivery Technologies GmbH (HEIDELTEC), offers a novel liposomal matrix system that enables the oral administration of peptide and protein drugs in a solid form, without the need for syringes.


The Heidelberg-based company is a spin-off from the pharmaceutical technology of the Ruprecht-Karls-University of Heidelberg, and is part of the EXIST research transfer program funded by the German Federal Ministry of Economics and Energy.


With its PEPTORAL® technology, HEIDELTEC services clients and licensees from the pharmaceutical industry and the life science sector. By offering them the opportunity to reformulate or newly formulate peptide and protein active ingredients for oral administration.  The PEPTORAL® technology uses an innovative, patent-pending, liposomal matrix formulation, which safely encapsulates the active substance during its passage through the stomach, and ensures intestinal absorption into the blood. It offers high storage stability and allows a controlled single dose of the active ingredients.


More information on the company and the team is available here.